Search

Your search keyword '"Napoleone Ferrara"' showing total 388 results

Search Constraints

Start Over You searched for: Author "Napoleone Ferrara" Remove constraint Author: "Napoleone Ferrara"
388 results on '"Napoleone Ferrara"'

Search Results

1. Development of a Semi-automated Computer-based Tool for the Quantification of Vascular Tortuosity in the Murine Retina

2. Applications of Deep Learning

3. Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer

4. Naturally occurring combinations of receptors from single cell transcriptomics in endothelial cells

5. LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy

6. Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways

7. Iron Metabolism in the Tumor Microenvironment: Contributions of Innate Immune Cells

8. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1

9. Endothelial cells regulate neural crest and second heart field morphogenesis

10. VEGF‐A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy

11. Multimodal Microvascular Imaging Reveals that Selective Inhibition of Class I PI3K Is Sufficient to Induce an Antivascular Response

12. Loss of vascular endothelial growth factor A (VEGFA) isoforms in granulosa cells using pDmrt-1-Cre or Amhr2-Cre reduces fertility by arresting follicular development and by reducing litter size in female mice.

13. Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1

14. Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature.

15. Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells.

17. Supplementary Figures 1-3 from Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas

20. Supplementary Data from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

21. Supplementary Figure 4 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

22. Data from Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma

23. Supplementary Figure 5 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

24. Supplementary Figure 2 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

25. Supplementary Figure 3 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

26. Supplementary Figure 5 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

27. Supplementary Figure Legends from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

28. Supplementary Figure 6 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

29. Supplementary Figure 1 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

30. CCR Translation for the Article from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

32. Data from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

33. Data from Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1

34. Supplementary Figure 1 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

35. Supplementary Figure 6 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

36. Data from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

37. Supplementary Figure 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

38. Supplementary Methods, Tables 1 - 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

39. Supplementary Figure 4 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

40. Supplementary Figures S1-S2 from Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1

41. Supplementary Figure 2 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

42. Data from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

43. Supplementary Figure 1 from Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma

48. Supplementary Figure Legends 1-6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

Catalog

Books, media, physical & digital resources